D-1514-2016 Class II Terminated
FDA drug recall D-1514-2016 was initiated by Sandoz Inc on Aug 24, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised. The recall status is terminated (terminated Jul 12, 2017). Affected quantity: a) 1,584 cartons; b) 62,170 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 28, 2016
- Initiation Date
- Aug 24, 2016
- Termination Date
- Jul 12, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 1,584 cartons; b) 62,170 vials
Product description
Phenylephrine HCI Injection, USP, 10mg/mL, packaged in a) 5 mL Vial, 50 mg/5 mL (NDC 66758-016-03), 25 x 5 mL Vials per carton (NDC 66758-016-04) and b) 10 mL Vials, 100 mg/10 mL (NDC 66758-017-01), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540.
Reason for recall
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #: a) 091914, Exp 09/16; b) 080114, Exp 08/16; 090414, 092614, Exp 09/16
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1514-2016
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026